{"filing":{"accession_number":"0001104659-26-082649","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"tm2618293d4_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926082649/tm2618293d4_8k.htm"},"events":[{"id":17309,"run_id":15489,"accession_number":"0001104659-26-082649","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses an At The Market (ATM) offering agreement entered into on March 10, 2025, under which Traws Pharma may offer and sell up to $5,575,709 of common stock shares through Citizens JMP Securities pursuant to an effective Form S-3 shelf registration and prospectus supplement dated July 10, 2026. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a key capital-raising mechanism commonly disclosed under Item 8.01 or Item 3.02.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15703,"accession_number":"0001104659-26-082649","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an At The Market (ATM) offering agreement entered into on March 10, 2025, under which Traws Pharma may offer and sell up to $5,575,709 of common stock shares through Citizens JMP Securities pursuant to an effective Form S-3 shelf registration and prospectus supplement dated July 10, 2026. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a key capital-raising mechanism commonly disclosed under Item 8.01 or Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:04:40.637682+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15703,"accession_number":"0001104659-26-082649","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an At The Market (ATM) offering agreement entered into on March 10, 2025, under which Traws Pharma may offer and sell up to $5,575,709 of common stock shares through Citizens JMP Securities pursuant to an effective Form S-3 shelf registration and prospectus supplement dated July 10, 2026. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a key capital-raising mechanism commonly disclosed under Item 8.01 or Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:04:40.637682+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-07-10"}]}